What is she best known for?
The fields of study she is best known for:
- Gene
- Cancer
- Internal medicine
The scientist’s investigation covers issues in Retinoblastoma, Genetics, Molecular biology, Mutation and Allele.
Her Retinoblastoma research entails a greater understanding of Gene.
Her study in Molecular biology is interdisciplinary in nature, drawing from both Chromosomal translocation, Psychological repression, Retinoblastoma protein, Promoter and Regulation of gene expression.
Brenda L. Gallie combines subjects such as Genetic counseling, Genotype, Retinal and Germline with her study of Mutation.
Her study focuses on the intersection of Allele and fields such as Genome with connections in the field of Esterase D.
Her Chromosome 13 research integrates issues from Loss of heterozygosity and Mitotic crossover.
Her most cited work include:
- Expression of recessive alleles by chromosomal mechanisms in retinoblastoma (1642 citations)
- Using expression profiling data to identify human microRNA targets. (354 citations)
- Using expression profiling data to identify human microRNA targets. (354 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of investigation include Retinoblastoma, Cancer research, Molecular biology, Genetics and Pathology.
Retinoblastoma is the subject of her research, which falls under Gene.
Her research in Cancer research intersects with topics in Cell culture, Gene expression, Carcinogenesis, Oncogene and Tumor progression.
Her work deals with themes such as Chromosome 13, Retinoblastoma protein and Exon, which intersect with Molecular biology.
Mutation, Allele, Germline mutation and Genetic counseling are subfields of Genetics in which her conducts study.
Her work in the fields of Chemotherapy, such as Vincristine and Chemotherapy regimen, intersects with other areas such as Intraocular Retinoblastoma.
She most often published in these fields:
- Retinoblastoma (72.85%)
- Cancer research (27.42%)
- Molecular biology (20.16%)
What were the highlights of her more recent work (between 2016-2021)?
- Retinoblastoma (72.85%)
- Cancer (12.10%)
- Enucleation (12.90%)
In recent papers she was focusing on the following fields of study:
Brenda L. Gallie mainly focuses on Retinoblastoma, Cancer, Enucleation, Radiology and Internal medicine.
She integrates Retinoblastoma with Intraocular Retinoblastoma in her research.
The concepts of her Enucleation study are interwoven with issues in Ophthalmology, White matter, Confidence interval and Monocular.
Her research integrates issues of Posterior pole, Trilateral retinoblastoma, Stage and Optic nerve in her study of Radiology.
As a part of the same scientific study, Brenda L. Gallie usually deals with the Internal medicine, concentrating on Oncology and frequently concerns with Patient advocacy and Ocular cancer.
Her Tumor suppressor gene study is focused on Genetics in general.
Between 2016 and 2021, her most popular works were:
- Genetics and Molecular Diagnostics in Retinoblastoma--An Update. (49 citations)
- Screening Children at Risk for Retinoblastoma: Consensus Report from the American Association of Ophthalmic Oncologists and Pathologists (35 citations)
- Optical Coherence Tomography-Guided Decisions in Retinoblastoma Management. (29 citations)
In her most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Brenda L. Gallie spends much of her time researching Retinoblastoma, Internal medicine, Cancer, Tumor suppressor gene and Oncology.
Her Leukocoria study, which is part of a larger body of work in Retinoblastoma, is frequently linked to Intraocular Retinoblastoma, bridging the gap between disciplines.
Her Leukocoria study also includes
- Stage most often made with reference to Extraocular Retinoblastoma,
- Pathological staging, which have a strong connection to Metastasis.
The Deferiprone, Blood transfusion, Randomized controlled trial and Anemia research she does as part of her general Internal medicine study is frequently linked to other disciplines of science, such as Deferasirox, therefore creating a link between diverse domains of science.
Brenda L. Gallie has researched Chemotherapy in several fields, including Hearing loss and Cumulative dose.
Her Genetic testing research incorporates themes from Cloning, Suppressor, Gene, Molecular cloning and Computational biology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
